Pharmacokinetics, Safety, and Tolerability of Selonsertib, an Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor, Following First-in-Human Single and Multiple Ascending Doses in Healthy Subjects

• Published in: Clinical pharmacokinetics Vol. 59; no. 9; pp. 1109 - 1117
• Main Authors: Nelson, Cara H., Etchevers, Kim, Yi, Saili, Breckenridge, David, Hepner, Mischa, Patel, Uptal, Ling, John, Mathias, Anita
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.09.2020; Springer Nature B.V
• Subjects: Apoptosis; Chemokines; Drug dosages; Food; Inflammation; Internal Medicine; Kinases; Laboratories; Ligands; Medicine; Medicine & Public Health; Original Research Article; Oxidative stress; Pharmacodynamics; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Phosphorylation; Urine; United States > US

Background Selonsertib is a first-in-class inhibitor of apoptosis signal-regulating kinase 1 (ASK1) with therapeutic potential for fibrotic diseases. This phase I study evaluated the safety, tolerability, pharmacokinetics (PK), and food effect of selonsertib in healthy subjects. Methods This was a d...